Come trattare lo Staphylococcus aureus resistente agli antibiotici
To treat antibiotic-resistant Staphylococcus aureus, phage therapy uses bacteriophages — natural viruses that specifically target and destroy Staphylococcus aureus. Practised without interruption since 1923 at the Eliava Institute in Tbilisi, Georgia, this method treats infections that antibiotics can no longer control: MRSA, osteomyelitis, prosthetic joint infections, and chronic wounds.
Why your Staphylococcus aureus resists antibiotics
If your staph infection persists despite multiple courses of antibiotics, it is neither your fault nor your doctor’s. It is a well-documented biological phenomenon. Staphylococcus aureus is one of the hardest bacteria to eradicate, for three specific reasons.
Biofilm. The bacteria form a protective coating — often invisible on medical imaging — that adheres to your tissues, bone, or a prosthetic implant. Inside this film, antibiotics can no longer properly penetrate. The bacteria are not killed; they are simply dormant, ready to wake up the moment treatment stops.
Acquired resistance. With each cycle of antibiotics, the most fragile bacteria die, but the most resistant ones survive and multiply. MRSA (Methicillin-Resistant Staphylococcus Aureus) has become one of the great challenges of global hospital medicine.
The therapeutic dead end. According to the World Health Organization, antimicrobial resistance is directly linked to approximately 1.27 million deaths worldwide each year. Resistant Staphylococcus aureus ranks among the most concerning pathogens.
When your doctor talks about amputation, palliative care, or a “lifelong” infection, they are not wrong — they are simply saying that with the tools available in Western medicine today, there is no solution left. But another tool exists elsewhere: bacteriophages. Their mechanism of action is radically different — see how phages differ from antibiotics.
Phage therapy: the solution Western medicine cannot offer you today
Bacteriophages are natural viruses that infect only bacteria — never human cells. Each type of phage targets a precise bacterial species, sometimes a single strain. Discovered in 1917 by Félix d’Hérelle at the Pasteur Institute, phages were abandoned in the West in favour of antibiotics but remained in continuous clinical use in Georgia.
For Staphylococcus aureus, anti-staph phages are among the most studied and the most effective in the world. The Eliava Institute has been continuously producing several cocktails active against S. aureus for nearly a century:
- Sb-1 — monovalent staphylococcal phage
- Pyo phage — polyvalent cocktail also targeting Staphylococcus
- Staphylococcal phage — cocktail specifically anti-staph
Unlike antibiotics, phages penetrate biofilm, self-replicate exactly where the bacteria are present, then disappear once the infection is cleared. They do not affect your microbiome, do not cause cross-resistance with antibiotics, and can be combined with them to amplify the effect.
In most Western countries, phage therapy is only available case by case, under compassionate use authorisations or specific clinical trial protocols. No Western laboratory produces phages for routine clinical use. For a resistant staph infection, you will not, to date, find a Western centre equipped to treat you. The Eliava Institute remains the only centre in the world offering continuous production, a personalised phagogram, and structured clinical follow-up for international patients.
How phage therapy for your staph infection actually works in Tbilisi
The general phage therapy protocol is the same whatever the bacterial target: sending the sample to Tbilisi, phagogram testing on your precise strain, preparation of a personalised cocktail, on-site application, and remote follow-up with Alain Lavit and the Eliava team.
For Staphylococcus aureus, what makes the difference is the choice of administration route, determined by where the infection is located:
- Intravenous — for staphylococcal septicaemia or deep diffuse osteomyelitis.
- Local application — for chronic skin wounds, open sinuses, fistulas, or drained abscesses.
- Instillation — directly into an infected prosthetic joint, or as peri-operative irrigation during surgical debridement.
- Inhalation — when staphylococcus colonises the respiratory tract (cystic fibrosis, chronic bronchial infections).
- Oral route — as an adjunct when staphylococcus is also present in the digestive tract.
Many cases combine several routes in parallel, decided by the Eliava physicians based on your full medical file and the mapping of your infection.
Patient testimonials: staph infections successfully treated in Tbilisi
Arm saved after 36 surgeries. Following an open fracture and a resistant Staphylococcus aureus infection, this French patient underwent 36 surgical procedures over five years. Amputation was the next step on the table. Several cycles of phage therapy at the Eliava Institute cleared the infection. His arm was saved, and he recovered near-complete use of the limb.
Knee prosthesis and septic shock. This patient had developed a Staphylococcus aureus infection on her total knee replacement, followed by septic shock that landed her in intensive care. Antibiotics were only partially controlling the infection, and the prosthesis was scheduled for removal. A targeted phage therapy cycle stabilised the infection; the prosthesis was preserved.
Bone and joint infection with recurrent septicaemia. A patient suffering for several years from chronic Staphylococcus aureus osteomyelitis, with septicaemia episodes whenever antibiotics were stopped. Phage therapy, after several stays in Tbilisi, ended the recurrences and allowed the gradual discontinuation of long-term antibiotics.
You will find all documented cases on the full patient testimonials page.
How much does phage therapy for Staphylococcus aureus cost, and how long should you plan for?
A complete treatment at the Eliava Institute for resistant Staphylococcus aureus includes medical consultations, phagogram, preparation of the personalised phage cocktail, on-site application, and accompaniment by an English-speaking interpreter. The overall cost is more accessible than most patients expect — in most cases, it is roughly the equivalent of a single prolonged hospital stay back home, with no guarantee of outcome there.
The average length of stay is 7 to 14 days: enough to initiate treatment, observe the first clinical and biological response, and adjust the formulation if needed. For severe infections (bone, joint, or prosthetic), a second cycle is sometimes recommended a few months later.
Detailed treatment pricing and the full organisation of a phage therapy stay in Georgia (flights, hotel, transfers, interpreter) are available on the dedicated pages.
Why the Eliava Institute and not another centre in the world
For the full history of the Eliava Institute, founded in 1923 in Tbilisi, see the dedicated page. What makes this centre unique for treating Staphylococcus aureus comes down to four precise points.
Specific expertise on Staphylococcus aureus. S. aureus has been one of the most thoroughly studied bacteria by Eliava teams since the 1930s. The centre holds what is likely the world’s largest collection of anti-S. aureus phages, continuously updated to keep pace with evolving resistant strains.
Recognised medical leadership. The therapeutic centre of the Institute is currently led by Davit Sturua, who oversees clinical care and the reception of international patients.
An official Western partnership. Alain Lavit, founder of Phage Therapy Georgia, has been the recognised official partner of the Eliava Institute for more than ten years. This recognition, formalised in a letter from the Institute’s leadership, allows him to coordinate directly the transmission of your file, the shipping of samples, the on-site reception, and post-treatment follow-up.
Scientific endorsement from France. French microbiologist Dr Alain Dublanchet, a recognised phage specialist, has been guiding patients towards phage therapy for several decades and confirms the quality of the work conducted at Eliava.
Frequently asked questions about treating Staphylococcus aureus with phage therapy
Does phage therapy really cure resistant Staphylococcus aureus?
In the majority of documented cases at the Eliava Institute, yes — provided your strain is sensitive to at least one phage in the collection, which the phagogram determines. No medical treatment guarantees 100 % success, but for antibiotic-resistant Staphylococcus aureus, phage therapy delivers results that Western medicine can no longer match today.
Should antibiotics be stopped before starting phage therapy?
No, in most cases. Phages and antibiotics are compatible and even synergistic: they can work together, with phages weakening the biofilm while antibiotics attack the released bacteria. The decision is made case by case by Eliava physicians, based on your antibiogram and clinical status.
How long before the first results show?
Clinical improvement is often observed within the first 7 to 14 days: reduced discharge, lower pain levels, progressive closure of a chronic wound, lower inflammatory markers (CRP, white cell count). For deep infections (bone or prosthetic), the timeline is measured in months.
Are there any known side effects?
Phages are remarkably well tolerated. No serious side effect has been reported in a century of clinical use at Eliava. During intravenous administration, you may experience a transient reaction — chills or low-grade fever for a few hours — which is the immune response to bacterial lysis, the sign that the phages are working.
Can MRSA be treated with phages?
Yes. A bacterium’s resistance to antibiotics has no biological link with its susceptibility to phages — the two mechanisms are entirely separate. An MRSA strain that escapes every antibiotic can still be perfectly susceptible to Eliava phages. This is precisely the territory where phage therapy is most useful.
Can I be treated remotely without travelling to Georgia?
In some cases, yes. You can send a sample to Eliava without travelling. After phagogram, personalised phages can be shipped back for administration locally under medical supervision. This option depends on the type of infection, your clinical status, and the route of administration required. A file review determines what is possible in your case.
What is the success rate for staphylococcus on prosthetic joints?
Prosthetic joint infections caused by Staphylococcus aureus are among the most frequently treated indications at the Eliava Institute, with over a century of clinical experience on staph infections. When the phagogram identifies at least one phage active on your strain, prosthesis preservation — rather than surgical removal — is achieved in the majority of cases. A French patient treated in Tbilisi for a Staphylococcus aureus infection on a total knee replacement, with septic shock, shares her experience: her full case is documented here. In France, the team led by Prof. Tristan Ferry at the Croix-Rousse Hospital (Lyon) published in 2020 the first French clinical results of the “PhagoDAIR” procedure on three patients in therapeutic deadlock — confirming on a smaller scale what has been daily practice in Tbilisi for decades.
Is phage therapy legal and authorised?
In Georgia, yes — it is an official medical practice, integrated into the health system since 1923. In most Western countries, it is available case by case (compassionate use authorisations in France, “Specials” route in the UK, expanded access in the US, named-patient basis across the EU). Seeking treatment in Georgia at a recognised centre is perfectly legal for international patients.
Check whether your Staphylococcus aureus can be treated with phage therapy
Complete the online medical questionnaire with your latest antibiogram, your most recent bacteriological report, and a summary of your medical history. Alain Lavit forwards your file to the Eliava physicians, who will tell you within a few days whether the specific phages required are available and suited to your infection.
No commitment. No fees. No marketing.